| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRNEPH.2017.16 |
| P698 | PubMed publication ID | 28218263 |
| P50 | author | Christopher D Byrne | Q38548520 |
| P2093 | author name string | Giovanni Targher | |
| P2860 | cites work | Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. | Q38606360 |
| Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 | ||
| Perspectives on Treatment for Nonalcoholic Steatohepatitis | Q38772446 | ||
| Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? | Q38772737 | ||
| Gut microbiome in chronic kidney disease: challenges and opportunities | Q38836354 | ||
| The Role of the Gut Microbiome on Chronic Kidney Disease. | Q38938184 | ||
| The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome | Q39018887 | ||
| Renal, metabolic and cardiovascular considerations of SGLT2 inhibition | Q39035951 | ||
| Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. | Q39299413 | ||
| Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States | Q40417686 | ||
| Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. | Q40468739 | ||
| Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. | Q41457655 | ||
| Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice | Q41643121 | ||
| Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept | Q41662018 | ||
| The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. | Q42090677 | ||
| Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice | Q42107886 | ||
| Massive gene amplification drives paediatric hepatocellular carcinoma caused by bile salt export pump deficiency | Q42219264 | ||
| Hepatic syndecan-1 changes associate with dyslipidemia after renal transplantation | Q42678793 | ||
| Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis | Q42791977 | ||
| Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice | Q43224118 | ||
| Emerging risk factors and markers of chronic kidney disease progression | Q43236381 | ||
| Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus | Q43674589 | ||
| Nonalcoholic steatohepatitis and increased risk of chronic kidney disease | Q44199606 | ||
| No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial | Q44997998 | ||
| Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. | Q45052723 | ||
| Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis | Q45070082 | ||
| Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis | Q45200394 | ||
| Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease | Q24601951 | ||
| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 | ||
| The gut microbiota and host health: a new clinical frontier | Q26785649 | ||
| Decoding cell death signals in liver inflammation | Q26823299 | ||
| Effect of redox modulating NRF2 activators on chronic kidney disease | Q26827726 | ||
| Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective | Q26863476 | ||
| The microbiology of butyrate formation in the human colon | Q28217318 | ||
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | Q28253122 | ||
| Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease | Q28394732 | ||
| Activation of the Liver X Receptor by Agonist TO901317 Improves Hepatic Insulin Resistance via Suppressing Reactive Oxygen Species and JNK Pathway | Q28546710 | ||
| Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis | Q29038812 | ||
| A metagenome-wide association study of gut microbiota in type 2 diabetes | Q29547726 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 | ||
| Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults | Q29617576 | ||
| Insulin resistance in chronic kidney disease: a systematic review | Q30244271 | ||
| Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis. | Q30248353 | ||
| Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening | Q30277347 | ||
| Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. | Q30278545 | ||
| Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. | Q30361789 | ||
| The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. | Q30382395 | ||
| Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways | Q30405346 | ||
| Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis | Q30592294 | ||
| n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions | Q30625279 | ||
| Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients | Q33308506 | ||
| Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. | Q33725646 | ||
| Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. | Q33773127 | ||
| Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis | Q33932951 | ||
| Phylogenetic relationships of butyrate-producing bacteria from the human gut. | Q33986987 | ||
| Links between ectopic fat and vascular disease in humans | Q34076155 | ||
| Gut metagenome in European women with normal, impaired and diabetic glucose control | Q34347521 | ||
| Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease | Q34357996 | ||
| Relationship between Kidney Function and Liver Histology in Subjects with Nonalcoholic Steatohepatitis | Q34362642 | ||
| Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk | Q34499496 | ||
| Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease | Q34540703 | ||
| p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease | Q34593224 | ||
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Q34676840 | ||
| Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism | Q34719267 | ||
| The Gordian Knot of dysbiosis, obesity and NAFLD. | Q34956813 | ||
| Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease | Q35033613 | ||
| Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis | Q35086412 | ||
| Micro RNAs in the development of non-alcoholic fatty liver disease | Q35127045 | ||
| Gut microbiome and nonalcoholic fatty liver diseases | Q35327402 | ||
| Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies | Q35528569 | ||
| The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. | Q35587723 | ||
| Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance | Q35631767 | ||
| Relationship between Obesity, Gut Microbiome and Hepatocellular Carcinoma Development | Q35653368 | ||
| CHOP links endoplasmic reticulum stress to NF-κB activation in the pathogenesis of nonalcoholic steatohepatitis | Q35717788 | ||
| Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease | Q35754305 | ||
| Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. | Q35757790 | ||
| The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes | Q35811523 | ||
| Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice | Q35840309 | ||
| Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus | Q35841020 | ||
| The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota | Q35850620 | ||
| Mechanisms Linking the Gut Microbiome and Glucose Metabolism | Q35944302 | ||
| High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis | Q35958233 | ||
| Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease | Q36138443 | ||
| p-Cresyl sulfate promotes insulin resistance associated with CKD | Q36509307 | ||
| Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994 | Q36584582 | ||
| Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease | Q36796750 | ||
| Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. | Q36818351 | ||
| Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease | Q36818384 | ||
| Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older | Q36885737 | ||
| Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis | Q37122480 | ||
| The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity. | Q37209898 | ||
| Non-alcoholic fatty liver and the gut microbiota | Q37215934 | ||
| Causes and metabolic consequences of Fatty liver | Q37250791 | ||
| Adipokines protecting CKD. | Q37270838 | ||
| Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. | Q45730273 | ||
| Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. | Q45800509 | ||
| Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction | Q46078911 | ||
| Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease | Q46083342 | ||
| Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity | Q46410788 | ||
| Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. | Q46712410 | ||
| Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study | Q46945399 | ||
| Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. | Q47765250 | ||
| A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. | Q51302141 | ||
| Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. | Q51355700 | ||
| Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. | Q51442516 | ||
| Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. | Q52931087 | ||
| Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | Q53084508 | ||
| Vitamin D counteracts fibrogenic TGF-β signalling in human hepatic stellate cells both receptor-dependently and independently. | Q53264260 | ||
| Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. | Q53269157 | ||
| Statin use and non-alcoholic steatohepatitis in at risk individuals. | Q53504568 | ||
| Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: A cross-sectional study. | Q54298808 | ||
| Distinct Roles for JNK and IKK Activation in Agouti-Related Peptide Neurons in the Development of Obesity and Insulin Resistance. | Q55069656 | ||
| The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice | Q57244037 | ||
| Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients | Q58209760 | ||
| Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial | Q60408831 | ||
| Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease | Q61337967 | ||
| Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease | Q83377328 | ||
| Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients | Q84006151 | ||
| Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more | Q85013803 | ||
| Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels | Q85195927 | ||
| The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients | Q86032588 | ||
| High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease | Q86925195 | ||
| Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice | Q87203689 | ||
| Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study | Q87417591 | ||
| Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes | Q87601214 | ||
| Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease | Q88031254 | ||
| 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the E | Q88263238 | ||
| Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease | Q37282300 | ||
| Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes | Q37319187 | ||
| Metabolic disturbances in non-alcoholic fatty liver disease. | Q37401367 | ||
| SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. | Q37575455 | ||
| The role of oxidative stress in chronic kidney disease. | Q37587310 | ||
| Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging | Q37641049 | ||
| Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms | Q37682486 | ||
| Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease | Q37794163 | ||
| Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments | Q37926944 | ||
| Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function | Q37941608 | ||
| Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? | Q37992604 | ||
| Targeting chemokines in proteinuria-induced renal disease | Q38026076 | ||
| Adiponectin: key player in the adipose tissue-liver crosstalk. | Q38033220 | ||
| Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis | Q38051955 | ||
| Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. | Q38080508 | ||
| Ectopic fat, insulin resistance and non-alcoholic fatty liver disease | Q38106497 | ||
| Noninvasive evaluation of NAFLD. | Q38141711 | ||
| Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations | Q38157936 | ||
| Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline | Q38169980 | ||
| KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. | Q38197453 | ||
| CKD and nonalcoholic fatty liver disease | Q38236189 | ||
| Galectin-3: an emerging all-out player in metabolic disorders and their complications | Q38258947 | ||
| MicroRNAs in kidney physiology and disease | Q38266791 | ||
| DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity | Q38293064 | ||
| NAFLD: a multisystem disease. | Q38446387 | ||
| Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. | Q38550285 | ||
| Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis | Q38551250 | ||
| Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease | Q38598077 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 297-310 | |
| P577 | publication date | 2017-02-20 | |
| P1433 | published in | Nature Reviews Nephrology | Q2079275 |
| P1476 | title | Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease | |
| P478 | volume | 13 |
| Q91063272 | A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial |
| Q64109827 | Accuracy of multi-echo Dixon sequence in quantification of hepatic steatosis in Chinese children and adolescents |
| Q49913361 | Activation of constitutive androstane receptor ameliorates renal ischemia-reperfusion induced liver and kidney injury |
| Q91764313 | Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease |
| Q92752460 | Associations between psychological distress and health-related behaviors among adults with chronic kidney disease |
| Q91826080 | Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease |
| Q90734876 | Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review |
| Q100467623 | Chronic Kidney Disease in Patients with Chronic Liver Disease: What Is the Price Tag? |
| Q47581786 | Clinical relevance of liver histopathology and different histological classifications of NASH in adults |
| Q64117585 | Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction |
| Q89634109 | Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan |
| Q92282740 | FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease |
| Q91829469 | Hepatic Steatosis Index Is Associated with Type 1 Diabetes Complications |
| Q100994725 | Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum |
| Q64239602 | Immunoregulatory Effect of Koumine on Nonalcoholic Fatty Liver Disease Rats |
| Q54985540 | Implication of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, and Subclinical Inflammation on Mild Renal Insufficiency. |
| Q58804230 | Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context |
| Q91612431 | Liver stiffness assessed by transient elastography as a potential indicator of chronic kidney disease in patients with nonalcoholic fatty liver disease |
| Q97652812 | MCD diet-induced steatohepatitis generates a diurnal rhythm of associated biomarkers and worsens liver injury in Klf10 deficient mice |
| Q92542287 | Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease |
| Q50108575 | Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease. |
| Q42365749 | NAFLD: Is There Anything New under the Sun? |
| Q47156332 | Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases |
| Q93379612 | Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden |
| Q49501260 | Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus |
| Q92128058 | Pathological Characteristics of Periodontal Disease in Patients with Chronic Kidney Disease and Kidney Transplantation |
| Q91654839 | Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation |
| Q64242788 | Presence of diabetic retinopathy is lower in type 2 diabetic patients with non-alcoholic fatty liver disease |
| Q33587143 | Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients |
| Q92625566 | Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD |
| Q92557963 | Transmembrane 6 superfamily member 2 167K allele improves renal function in children with obesity |
| Q91851737 | Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement |
Search more.